Description
The VA is issuing an intent‑to‑sole‑source notice for a five‑year Indefinite‑Delivery‑Indefinite‑Quantity (IDIQ) contract to provide proprietary AlloMap® gene‑expression profiling and AlloSure® donor‑derived cell‑free DNA assays for post‑heart‑transplant rejection surveillance. The contract will be firm‑fixed‑price, with five one‑year task‑order periods, and will require the vendor to supply testing services, mobile phlebotomy, specimen logistics, and detailed reporting for approximately 165 tests per year. The solicitation calls for a capability statement (no price proposal) by the deadline, and the VA may still decide to compete the requirement if viable responses are received.
• Scope: Laboratory testing (AlloMap & AlloSure), mobile phlebotomy, specimen handling, and result reporting for VA heart‑transplant patients.
• Volume: ~100 AlloMap and ~65 AlloSure tests annually (≈165 total tests per year).
• Contract terms: 5‑year IDIQ, firm‑fixed‑price, with annual task‑order options; all invoicing electronic via VA‑approved systems.
• Requirements: CLIA‑accredited lab, CDC accreditation, board‑certified Laboratory Director, compliance with extensive VA security, privacy, and data‑destruction mandates.
• Eligibility: Open to any vendor, but the VA believes only CareDx can supply the proprietary assays; other vendors may submit a capability statement for consideration.